349 related articles for article (PubMed ID: 36267567)
1. Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.
Yang B; Lu L; Zhou D; Fan W; Barbier-Torres L; Steggerda J; Yang H; Yang X
Front Endocrinol (Lausanne); 2022; 13():1007944. PubMed ID: 36267567
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease.
Yang B; Yang X; Tan X; Lu L; Fan W; Barbier-Torres L; Steggerda J; Liu T; Yang H
Can J Gastroenterol Hepatol; 2022; 2022():6799414. PubMed ID: 36397950
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
[TBL] [Abstract][Full Text] [Related]
4. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.
Yang B; Lu L; Zhou D; Fan W; Barbier-Torres L; Steggerda J; Yang H; Yang X
Front Endocrinol (Lausanne); 2023; 14():1284809. PubMed ID: 37842309
[TBL] [Abstract][Full Text] [Related]
6. Hepatokines and non-alcoholic fatty liver disease.
Lebensztejn DM; Flisiak-Jackiewicz M; Białokoz-Kalinowska I; Bobrus-Chociej A; Kowalska I
Acta Biochim Pol; 2016; 63(3):459-67. PubMed ID: 27262842
[TBL] [Abstract][Full Text] [Related]
7. Hepatokines and adipokines in NASH-related hepatocellular carcinoma.
Kucukoglu O; Sowa JP; Mazzolini GD; Syn WK; Canbay A
J Hepatol; 2021 Feb; 74(2):442-457. PubMed ID: 33161047
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
Wiering L; Subramanian P; Hammerich L
Cell Mol Gastroenterol Hepatol; 2023; 15(6):1277-1292. PubMed ID: 36828280
[TBL] [Abstract][Full Text] [Related]
9. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
12. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
13. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
14. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
16. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
18. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
19. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Cernea S; Onișor D
World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
[TBL] [Abstract][Full Text] [Related]
20. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
